Semaglutide vs Liraglutide
Both are acylated GLP-1 analogues from the same developer. Liraglutide is dosed daily; semaglutide’s modifications give it a roughly week-long half-life, and in the STEP 8 trial it produced greater weight loss than liraglutide.
Semaglutide
A long-acting GLP-1 receptor agonist, the reference molecule of the modern incretin era in both injectable and oral form.
BEST STUDIED FOR
Incretin & metabolic
Read the cited profile →
Liraglutide
A once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analogue developed by acylation, predecessor to semaglutide.
BEST STUDIED FOR
Incretin & metabolic
Read the cited profile →
SIDE BY SIDE
| Semaglutide | Liraglutide | |
|---|---|---|
| The key difference | Once-weekly (also oral) | Once-daily |
| Class | Incretin & metabolic | Incretin & metabolic |
| Mechanism | Semaglutide is a GLP-1 analogue with amino-acid substitutions and a C18 fatty-diacid chain that binds albumin, extending its half-life to about a week. | Liraglutide carries a C16 fatty-acid side chain that allows albumin binding and self-association, extending its half-life to about 13 hours. |
| Status | Approved medicine (type 2 diabetes and chronic weight management) in many countries, with a large phase 3 programme (STEP, SUSTAIN, SELECT). Prescription-only in South Africa. | Approved for type 2 diabetes and (at a higher dose) weight management; trialled in adolescents and children. Prescription-only in South Africa. |
| Reported safety signals | Reviews document gastrointestinal effects as the most common; pancreatitis, gallbladder events and the effect on lean mass are active topics. Trials show weight regain after stopping. | Gastrointestinal effects predominate; network meta-analyses compare its efficacy and safety with semaglutide and tirzepatide; weight regain after interruption is documented. |
| A key study | Reviews the safety profile of semaglutide across subcutaneous and oral formulations. (Front Endocrinol (Lausanne) 2021, PMID 34305810) | Traces how acylation strategies extended GLP-1’s half-life, first in liraglutide and then semaglutide. (Front Endocrinol (Lausanne) 2019, PMID 31031702) |
WHEN TO RESEARCH WHICH
Semaglutide is the more potent, longer-acting successor; liraglutide has the longer safety record. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Semaglutide] Safety of Semaglutide — Front Endocrinol (Lausanne) 2021. PMID 34305810
- [Semaglutide] A systematic review of the effect of semaglutide on lean mass: insights from clinical trials — Expert Opin Pharmacother 2024. PMID 38629387
- [Semaglutide] Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial — JAMA 2021. PMID 33755728
- [Liraglutide] The Discovery and Development of Liraglutide and Semaglutide — Front Endocrinol (Lausanne) 2019. PMID 31031702
- [Liraglutide] A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — N Engl J Med 2015. PMID 26132939
- [Liraglutide] Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies — J Clin Med 2025. PMID 40507553
FREQUENTLY ASKED
What is the difference between Semaglutide and Liraglutide?
Both are acylated GLP-1 analogues from the same developer. Liraglutide is dosed daily; semaglutide’s modifications give it a roughly week-long half-life, and in the STEP 8 trial it produced greater weight loss than liraglutide.
What is the regulatory status of Semaglutide and Liraglutide?
Semaglutide: Approved medicine (type 2 diabetes and chronic weight management) in many countries, with a large phase 3 programme (STEP, SUSTAIN, SELECT). Prescription-only in South Africa. Liraglutide: Approved for type 2 diabetes and (at a higher dose) weight management; trialled in adolescents and children. Prescription-only in South Africa.
What safety signals have been reported?
Semaglutide: Reviews document gastrointestinal effects as the most common; pancreatitis, gallbladder events and the effect on lean mass are active topics. Trials show weight regain after stopping. Liraglutide: Gastrointestinal effects predominate; network meta-analyses compare its efficacy and safety with semaglutide and tirzepatide; weight regain after interruption is documented.
Which studies is this comparison based on?
For Semaglutide: “Safety of Semaglutide” (PMID 34305810); “A systematic review of the effect of semaglutide on lean mass: insights from clinical trials” (PMID 38629387); “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial” (PMID 33755728). For Liraglutide: “The Discovery and Development of Liraglutide and Semaglutide” (PMID 31031702); “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management” (PMID 26132939); “Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies” (PMID 40507553).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use